CAG REPEAT NUMBER IN THE ANDROGEN RECEPTOR
GENE AND PROSTATE CANCER
Madjunkova S, Eftimov A, Georgiev V, Petrovski D, Dimovski AJ, Plaseska-
Karanfi lska D,
*Corresponding Author: Professor Dr. Dijana Plaseska-Karanfi lska, Macedonian Academy of Sciences
and Arts, Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, Av. Krste
Misirkov 2, POB 428, 1000 Skopje, Republic of Macedonia; Tel.: +389-2-3235-410; Fax: +389-2-3115-
434; E-mail: dijana@manu.edu.mk
page: 31
download article in pdf format
|
|
Abstract
Prostate cancer (PC) is the second leading cause
of cancer deaths in men. The effects of androgens
on prostatic tissue are mediated by the androgen receptor
(AR) gene. The 5’ end of exon 1 of the AR
gene includes a polymorphic CAG triplet repeat that
numbers between 10 to 36 in the normal population.
The length of the CAG repeats is inversely related
to the transactivation function of the AR gene.
There is controversy over association between short
CAG repeat numbers in the AR gene and PC. This
retrospective case-control study evaluates the possible
effect of short CAG repeats on the AR gene
in prostate cancer risk in Macedonian males. A total
of 392 male subjects, 134 PC patients, 106 patients
with benign prostatic hyperplasia (BPH) and
152 males from the general Macedonian population
were enrolled in this study. The CAG repeat length
was determined by fl uorescent polymerase chain reaction
(PCR) amplifi cation of exon1 of the AR gene
followed by capillary electrophoresis (CE) on a genetic
analyzer. The mean repeat length in PC patients
was 21.5 2.65, in controls 22.28 2.86 (p =
0.009) and in BPH patients 22.1 2.52 (p = 0.038).
Short CAG repeats (<19) were found in 21.64% of
PC patients vs. 9.43% in BPH patients (p = 0.0154).
We also found an association of low Gleason score
(<7) with short CAG repeat (<19) in PC patients (p
= 0.0306), and no association between the age at
diagnosis of PC and BPH and CAG repeat length.
These results suggest that reduced CAG repeat
length may be associated with increased prostate
cancer risk in Macedonian men.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
